Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D00PNU
|
|||
Former ID |
DIB013284
|
|||
Drug Name |
TGN-1412
|
|||
Synonyms |
SuperMAB; CD28-SuperMAB; Superagonistic monoclonal antibodies, TeGenero
Click to Show/Hide
|
|||
Drug Type |
Antibody
|
|||
Indication | Autoimmune diabetes [ICD-11: 5A10] | Discontinued in Phase 1 | [1] | |
Company |
TeGenero ImmunoTherapeutics AG
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | T-cell-specific surface glycoprotein CD28 (CD28) | Target Info | . | [2] |
KEGG Pathway | Cell adhesion molecules (CAMs) | |||
T cell receptor signaling pathway | ||||
Intestinal immune network for IgA production | ||||
Type I diabetes mellitus | ||||
Measles | ||||
Autoimmune thyroid disease | ||||
Systemic lupus erythematosus | ||||
Rheumatoid arthritis | ||||
Allograft rejection | ||||
Graft-versus-host disease | ||||
Viral myocarditis | ||||
NetPath Pathway | TCR Signaling Pathway | |||
Panther Pathway | T cell activation | |||
Pathway Interaction Database | TCR signaling in naï | |||
TCR signaling in naï | ||||
IL12 signaling mediated by STAT4 | ||||
Reactome | PIP3 activates AKT signaling | |||
Constitutive Signaling by Aberrant PI3K in Cancer | ||||
CD28 co-stimulation | ||||
CD28 dependent PI3K/Akt signaling | ||||
CD28 dependent Vav1 pathway | ||||
WikiPathways | TCR Signaling Pathway | |||
Inflammatory Response Pathway | ||||
Host Interactions of HIV factors | ||||
PIP3 activates AKT signaling | ||||
T-Cell Receptor and Co-stimulatory Signaling | ||||
Allograft Rejection | ||||
Costimulation by the CD28 family |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020365) | |||
REF 2 | TGN1412: From Discovery to Disaster. J Young Pharm. 2010 Jul-Sep; 2(3): 332-336. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.